Recruitment strategies and participant motivations in a digital randomized controlled trial for the prevention of anxiety disorders: the prevANS study - Takeaways - MDSpire

Recruitment strategies and participant motivations in a digital randomized controlled trial for the prevention of anxiety disorders: the prevANS study

  • By

  • Cristina García-Huércano

  • Sonia Conejo-Cerón

  • Alberto Rodríguez-Morejón

  • Carmela Martínez-Vispo

  • Natalia Sánchez-Aguadero

  • Olaya Tamayo-Morales

  • Patricia Moreno-Peral

  • May 13, 2026

Share

  • 1

    The prevANS study aimed to evaluate recruitment strategies for a digital intervention targeting anxiety disorder prevention.

  • 2

    Over 26 months, 6,017 individuals initiated screening, resulting in a 17.5% enrollment conversion rate.

  • 3

    Social media and university dissemination were the most effective recruitment strategies, with word of mouth also significantly impacting enrollment.

  • 4

    Participants' motivations for enrolling included helping others, health-related issues, and personal benefits.

  • 5

    Tailoring recruitment strategies to the target population can enhance participant engagement in digital mental health trials.

Original Source(s)

Recruitment strategies and participant motivations in a digital randomized controlled trial for the prevention of anxiety disorders: the prevANS study

  • by Cristina García-Huércano, Sonia Conejo-Cerón, Alberto Rodríguez-Morejón, Carmela Martínez-Vispo, Natalia Sánchez-Aguadero, Olaya Tamayo-Morales, Patricia Moreno-Peral

  • May 13, 2026

Related Content

Psilocybin for Cocaine Use: Signal or Noise?

Pilot randomized study suggests possible benefit, but blinding concerns and limited generalizability complicate interpretation

Semaglutide Tested in Alcohol Use Disorder

Randomized trial found improvements in alcohol consumption and metabolic outcomes, with gastrointestinal adverse events more common with treatment

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.